Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PTEN |
Variant | L194fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | PTEN L194fs results in a change in the amino acid sequence of the Pten protein beginning at aa 194 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). L194fs has not been characterized, however, due to the effects of other truncation mutations downstream of L194 (PMID: 10468583), is predicted to lead to a loss of Pten protein function. |
Associated Drug Resistance | |
Category Variants Paths |
PTEN mutant PTEN inact mut PTEN L194fs |
Transcript | NM_000314.8 |
gDNA | chr10:g.(87952204_87952205) |
cDNA | c.(580_579) |
Protein | p.L194fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000314.8 | chr10:g.(87952204_87952205) | c.(580_579) | p.L194fs | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN L194fs | thyroid cancer | predicted - sensitive | Ipilimumab + Nivolumab + Temsirolimus | Case Reports/Case Series | Actionable | In a clinical case study, the addition of Torisel (temsirolimus) to the combination treatment of Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a partial response with a decrease in target lesion size in a patient with poorly differentiated thyroid cancer harboring PTEN L194fs, along with TP53 F270S, who remained on treatment for 6 months (PMID: 38356955). | 38356955 |